Chlorhexidine Reduced Amyloid Plaques in Animal Study

Researchers found that the compound modified protein expression in mice, though clinical safety remains unproven.

Updated on Sept. 29, 2026 in Alzheimer’s

A glass petri dish with cell cultures sits on a clean, stainless-steel laboratory bench under cool, clinical lighting. — Researchers identified that chlorhexidine modulates BACE1 expression, successfully reducing amyloid plaque burden in preclinical mouse models of Alzheimer's disease. AI Illustration. Upload story photo >

Live Poll

Is it a better research approach to target gene expression rather than direct chemical inhibition?

A laboratory study found that the compound chlorhexidine altered BACE1 expression, leading to a reduction in amyloid plaque burden in Alzheimer's disease mouse models. These findings offer a potential new approach to target protein pathways associated with the condition.

Why it matters

Previous Alzheimer's trials targeting BACE1 through active-site inhibition have faced significant efficacy and safety hurdles. This research explores a different regulatory pathway to address the protein, though it is currently limited to preclinical models.

In an 8-week study, APP/PS1 transgenic mice treated with 10 mg/kg of daily oral chlorhexidine showed reduced amyloid plaque burden and improved behavioral performance. The researchers utilized RNA-seq and reporter tests to confirm the compound's effect on BACE1 expression.

The details

The treatment works by modulating BACE1 expression, an enzyme critical for the production of amyloid-beta proteins that form brain plaques. Specifically, chlorhexidine interacts with a SOCS3-dependent pathway, where it suppresses the BACE1 promoter. This regulatory mechanism was verified in human embryonic stem cell-derived neurons, confirming the response relies on specific distal elements within the promoter region.

Dosing began when the mice reached 9 months of age.
The treatment duration for the mice lasted 8 weeks.

Health Landscape

This research marks a pivot from traditional active-site BACE1 inhibitors, which failed in previous clinical trials due to efficacy and safety limitations. It reflects a broader trend in Alzheimer's science toward investigating regulatory pathways that control the production of pathological proteins.

This remains an early-stage laboratory finding, and there are currently no clinical implications for your health or treatment. If you are managing cognitive health, it is always best to discuss ongoing research updates and current management strategies with your primary care physician.

The takeaway

While this study shows promise in an animal model, it is too early to determine if this pathway will be safe or effective in humans. Readers should view this as foundational research rather than a near-term change to standard care or therapeutic recommendations.